CTOs on the Move

Mundipharma

www.mundipharma.com

 
The Mundipharma story, spanning over six decades, is one that brings together a visionary approach and a pioneering spirit – and is best told through our patients, our employees and the communities in which we serve. Our dedication to putting patients at the heart of every business decision has ensured that we continue to grow and more importantly, improve the lives of the people who need our medicines the most. That foundation has not only delivered significant results, but is a reflection of our ability to convert entrepreneurism and innovation into business success. We are focused on the transformation of ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Philippe Mazas
Chief Information Officer Profile

Similar Companies

Brooklyn Laser

Brooklyn Laser is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elk Hill

Elk Hill enables children and families to transform overwhelming challenges into successful futures by offering behvioral health and education services.

Afecta Pharmaceuticals

Afecta Pharmaceuticals is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beech Brook

Helping children & families thrive by promoting healthy child development, strengthening the ability to overcome adversity, & enhancing family health & stability.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.